| Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial R Stupp, S Taillibert, A Kanner, W Read, DM Steinberg, B Lhermitte, ... Jama 318 (23), 2306-2316, 2017 | 2060 | 2017 |
| Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial A Malmström, BH Grønberg, C Marosi, R Stupp, D Frappaz, H Schultz, ... The lancet oncology 13 (9), 916-926, 2012 | 1430* | 2012 |
| A colorectal cancer classification system that associates cellular phenotype and responses to therapy A Sadanandam, CA Lyssiotis, K Homicsko, EA Collisson, WJ Gibb, ... Nature medicine 19 (5), 619-625, 2013 | 1072 | 2013 |
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1013 | 2014 |
| Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of … LB Nabors, KL Fink, T Mikkelsen, D Grujicic, R Tarnawski, DH Nam, ... Neuro-oncology 17 (5), 708-717, 2015 | 230 | 2015 |
| Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with … A Malmström, BH Grønberg, C Marosi, R Stupp, D Frappaz, H Schultz, ... Lancet Oncol 13 (9), 916-926, 2012 | 210 | 2012 |
| Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation … W Wick, T Gorlia, P Bady, M Platten, MJ Van Den Bent, MJB Taphoorn, ... Clinical cancer research 22 (19), 4797-4806, 2016 | 138 | 2016 |
| Mutations in tubulin genes are frequent causes of various foetal malformations of cortical development including microlissencephaly C Fallet-Bianco, A Laquerrière, K Poirier, F Razavi, F Guimiot, P Dias, ... Acta neuropathologica communications 2, 1-22, 2014 | 117 | 2014 |
| European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... Lancet Oncol 15 (10), 1100-1108, 2014 | 89 | 2014 |
| Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell … KF Deml, HU Schildhaus, E Compérat, A von Teichman, M Storz, ... The American journal of surgical pathology 39 (7), 889-901, 2015 | 77 | 2015 |
| EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma E Franceschi, R Stupp, MJ Van Den Bent, C Van Herpen, ... Neuro-oncology 14 (12), 1503-1510, 2012 | 72 | 2012 |
| Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1 P Sievers, R Appay, D Schrimpf, D Stichel, DE Reuss, AK Wefers, ... Acta neuropathologica 138, 497-504, 2019 | 71 | 2019 |
| Different effects of the Cdx1 and Cdx2 homeobox genes in a murine model of intestinal inflammation A Calon, I Gross, B Lhermitte, E Martin, F Beck, B Duclos, M Kedinger, ... Gut 56 (12), 1688-1695, 2007 | 54 | 2007 |
| Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation I Gross, B Lhermitte, C Domon-Dell, I Duluc, E Martin, C Gaiddon, ... Oncogene 24 (54), 7955-7963, 2005 | 54 | 2005 |
| Methylation of the hTERT Promoter: A Novel Cancer Biomarker for Leptomeningeal Metastasis Detection in Cerebrospinal Fluids S Bougel, B Lhermitte, G Gallagher, JC de Flaugergues, RC Janzer, ... Clinical Cancer Research 19 (8), 2216-2223, 2013 | 49 | 2013 |
| Combination of MRI and dynamic FET PET for initial glioma grading V Dunet, P Maeder, M Nicod-Lalonde, B Lhermitte, C Pollo, J Bloch, ... Nuklearmedizin-NuclearMedicine 53 (04), 155-161, 2014 | 44 | 2014 |
| Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment B Lhermitte, C Egele, N Weingertner, D Ambrosetti, B Dadone, V Kubiniek, ... Virchows Archiv 470, 21-27, 2017 | 43 | 2017 |
| Interleukin‐32 contributes to human nonalcoholic fatty liver disease and insulin resistance N Dali‐Youcef, M Vix, F Costantino, H El‐Saghire, B Lhermitte, C Callari, ... Hepatology communications 3 (9), 1205-1220, 2019 | 42 | 2019 |
| Fragment N2, a caspase‐3‐generated RasGAP fragment, inhibits breast cancer metastatic progression D Barras, G Lorusso, B Lhermitte, D Viertl, C Rüegg, C Widmann International journal of cancer 135 (1), 242-247, 2014 | 41 | 2014 |
| FDOPA PET-CT of nonenhancing brain tumors C Bund, C Heimburger, A Imperiale, B Lhermitte, MP Chenard, F Lefebvre, ... Clinical Nuclear Medicine 42 (4), 250-257, 2017 | 35 | 2017 |
